Placement Fully Funds Completion of XanADu Alzheimers Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- R&D Rebate Received Totalling $1.22 Million
- Quarterly Update & Appendix 4C
- Final Major Market Patent Granted for Xanamem
- First Patient Completes Landmark Alzheimers Disease Trial
- First UK patient treated in ground-breaking clinical trial
Later from Actinogen Medical
- Early Efficacy & Safety Data Planned for XanADu Trial
- Prospectus
- December 2017 Quarterly Report
- New Data Supports Cortisol Hypothesis
- Strong Recruitment Progress in Alzheimers Trial
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical